Other Deal Trends 2026: Activity Surges 3400% in 6 Months

34 deals classified as "other" closed between February 23 and August 23, 2026 — up from exactly zero in the prior six-month window. That's a 3400% increase, and it's not a data artifact. Pharma's largest acquirers are aggressively moving into enabling technology platforms, tools companies, and cross-sector assets that don't fit neatly into traditional therapeutic area classifications, and the deal sizes — headlined by Merck KGaA's $11.3B Bio-Techne acquisition — make clear this isn't exploratory spending.

The Data — Other Deal Activity, Period over Period

The jump from zero to 34 warrants context. "Other" in deal databases typically captures transactions that span multiple therapeutic areas, involve platform technologies (protein sciences, AI-driven drug design, reagents, diagnostics), or represent corporate-level acquisitions where the asset isn't a single clinical-stage molecule. The prior period's zero count reflects both a genuine lull in this category and, arguably, the tail end of a conservative capital allocation cycle that kept Big Pharma focused on bolt-on clinical-stage acquisitions. The floodgates opened in Q2 2026.

What's Driving the Trend

Three forces converge to explain the explosion in other licensing 2026 activity and outright acquisitions in this category.

First, platform hunger. Big Pharma's pipeline gaps aren't just about molecules anymore. After watching Novo Nordisk build a GLP-1 empire partly on proprietary delivery and manufacturing technology, boards at Merck KGaA, Pfizer, and Novartis are mandating investment in upstream capabilities — protein engineering platforms, AI-native discovery engines, and biologics tools. Merck KGaA's pursuit of Bio-Techne is the clearest signal: they paid $11.3B not for a drug, but for a protein sciences and diagnostics infrastructure that feeds every stage of R&D. Novartis's deal with Generate:Biomedicines follows the same logic — acquiring generative biology capabilities to internalize what was previously outsourced.

Second, category blurring. The lines between biopharma, diagnostics, life science tools, and AI are dissolving. Deals that five years ago would have been classified under "oncology" or "immunology" now span so many modalities and indications that they default to "other." This isn't a taxonomy failure — it's the market telling us that the most strategically important assets in 2026 are horizontal platforms, not vertical therapeutic plays. BD teams that still organize their search by TA are structurally missing these opportunities.

Third, the compressed patent cliff timeline. With over $200B in branded revenue exposed to LOE between 2026 and 2030 (per Evaluate Pharma estimates), pharma companies are diversifying beyond traditional licensing. Acquiring tools and platform companies offers a hedge: these assets generate recurring revenue, have lower binary risk than clinical-stage molecules, and can be accretive to earnings immediately — a profile that boards under LOE pressure find compelling.

Notable Deals

Merck KGaA / Bio-Techne ($11.3B): This is the defining deal of the cycle. Merck KGaA's Life Science division — already a top-three player in bioprocess and research reagents — absorbs Bio-Techne's protein sciences, advanced cell analysis, and diagnostics portfolio. The $11.3B total deal value with no milestone structure (upfront equals TDV) signals full conviction. Merck KGaA paid roughly 9x Bio-Techne's trailing revenue — a premium justified by the target's 65%+ gross margins and entrenched position across 130,000+ research customers. For BD teams, this deal resets the valuation ceiling for life science tools companies and makes every remaining independent platform in the space an acquisition target.

YaoPharma / Pfizer ($150M upfront, $2.05B TDV): Pfizer's deal with China's YaoPharma represents the opposite end of the structural spectrum — a traditional licensing architecture (7.3% upfront-to-TDV ratio) applied to what appears to be a regional commercial expansion play. The $150M upfront is conservative for Pfizer, but the $2.05B total deal value implies substantial commercial milestones tied to China market access. This deal signals Pfizer's willingness to pay for established distribution infrastructure in markets where building organically has proven slow and expensive.

Generate:Biomedicines / Novartis: Financial terms remain undisclosed, but the strategic signal is unmistakable. Novartis is buying generative AI-driven protein design capability — the same thesis that drove their earlier deals in machine learning-assisted drug discovery, now taken to a platform-level commitment. This deal will likely set a benchmark for AI-bio platform valuations once terms surface in SEC filings. Refer to our Deal Benchmarks for comparables across AI-bio transactions.

What This Means for BD Teams Right Now

If you're selling a platform asset, this is your market. The data is unambiguous: buyer appetite for "other" category assets went from dormant to hyperactive in under six months. Valuation multiples are expanding — Bio-Techne's 9x revenue is 30–40% above where tools companies traded in M&A two years ago. If you're a biotech founder running a platform company with biopharma applications, your comp set just got dramatically more favorable. Use Solidus to benchmark your deal against the current multiples before entering term sheet discussions.

If you're buying, speed matters more than precision. The 34-deal wave in six months means competitive dynamics are intensifying. Multiple large pharma companies are pursuing the same category of assets simultaneously. Merck KGaA and Novartis both closed major platform deals within three days of each other — that's not coincidence, it's parallel strategic urgency. BD teams running sequential evaluation processes will lose to those running parallel tracks with pre-approved term sheet frameworks.

Deal structures are shifting. The Bio-Techne deal — $11.3B all-upfront, no milestones — represents the high end, but even mid-size deals in this category are moving toward heavier upfront weighting. YaoPharma's 7.3% upfront ratio looks like an outlier driven by regional market risk. For platform and tools assets in Western markets, expect upfront-to-TDV ratios of 40–60%, with buyers willing to pay premiums for clean acquisition structures that avoid earnout disputes. Option-based licensing for platform technologies is losing favor because buyers realized that optionality creates misaligned incentives when the asset is foundational to R&D infrastructure.

The classification itself is the insight. If your scouting team isn't actively monitoring "other" category deal flow, you're missing the fastest-growing segment of biopharma M&A. Set up alerts. Build a dedicated tracker. The next $10B+ deal in this space is probably six months away.

Benchmark your deal against current market rates using the Ambrosia calculator — updated with Q2 2026 transaction data including the deals analyzed above.